Physician profile
Beth A Brown
NPI 1184958837
$9,204.83
in general payments reported to CMS, 2019-2025
33 companies · $1,771 in 2025
The $1,771 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,067 · 2022: $1,857 · 2023: $1,679 · 2024: $1,831 · 2025: $1,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,280.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,812.70 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,544.64 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $1,502.55 | 2021-2025 | Belbuca, Xtampza |
| Pfizer INC. | $640.36 | 2023-2025 | |
| Relievant Medsystems, INC. | $414.81 | 2022-2023 | Intracept |
| Ibsa Pharma INC. | $337.54 | 2021-2025 | Tirosint, Tirosint, Licart |
| Azurity Pharmaceuticals, INC. | $332.46 | 2023-2025 | Horizant, Horizant |
| Vertex Pharmaceuticals Incorporated | $306.70 | 2025 | |
| Amgen INC. | $302.75 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $278.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $236.49 | 2021-2025 | Ztlido |
| Arbor Pharmaceuticals, INC. | $191.93 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $180.02 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $143.03 | 2021-2023 | Ajovy |
| Lilly USA, LLC | $134.77 | 2022-2024 | Emgality, Reyvow |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $119.73 | 2021-2023 | Gralise |
| Grt US Holding, INC. | $86.24 | 2021 | |
| Allergan, INC. | $64.67 | 2021-2022 | |
| Redhill Biopharma INC. | $64.57 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $61.29 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.00 | 2021 | |
| Hikma Pharmaceuticals USA | $52.97 | 2021-2024 | Kloxxado |
| Virtus Pharmaceuticals LLC | $52.78 | 2021-2023 | Levorphanol Tartrate |
| Indivior INC. | $52.27 | 2021-2022 | |
| Medtronic, INC. | $51.06 | 2023-2024 | Synchromedii, Accurian |
| Upsher-Smith Laboratories LLC | $36.11 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $34.88 | 2022-2023 | Seglentis |
| Horizon Therapeutics Plc | $29.90 | 2021 | |
| Bioventus LLC | $22.51 | 2022 | |
| Boston Scientific Corporation | $21.92 | 2024 | Intracept |
| West Therapeutics Development, LLC | $16.46 | 2021 | |
| Tonix Medicines, INC. | $16.12 | 2025 | Tonmya |
| Mml US, INC. | $5.60 | 2025 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.